Bella Vida TMS now offers Brixadi, a long-acting buprenorphine injection that eases cravings and withdrawal for adults with opioid use disorder. Start with flexible weekly dosing and transition to convenient monthly maintenance. In-clinic doses are paired with therapy and recovery supports to keep you on track.
Brixadi® Injections for OUD — Weekly & Monthly Options
Overview:
Brixadi is a long-acting form of buprenorphine, a partial opioid agonist used for OUD. After a small, subcutaneous injection given by our clinicians, the medicine forms a depot under the skin that slowly releases for a full week or a month, depending on the product and dose. Buprenorphine binds opioid receptors with high affinity but only partially activates them. This stabilizes brain chemistry, easing withdrawal, cutting cravings, and blunting the rewarding effects of other opioids (e.g., fentanyl or oxycodone) if they’re used. Because buprenorphine has a “ceiling effect,” it causes far less respiratory depression than full opioids, though combining it with sedatives or alcohol can still be risky. The steady release delivered by Brixadi reduces daily ups and downs, supports adherence, and provides a flexible path—weekly during early stabilization and monthly for maintenance—while we pair it with counseling, recovery supports, and routine follow-ups to adjust dosing.
Fast Acting Treatment
Benefits of Brixadi:
- Flexible dosing: weekly for early stabilization or dose-finding; monthly for convenient maintenance.
- No daily pills—fewer missed doses, less stigma, lower diversion risk.
- Steady buprenorphine levels reduce highs/lows and keep cravings and withdrawal in check.
- High receptor affinity can blunt the effects of other opioids if used.
- Clinician-administered injections ensure correct dosing and safe handling.
- Supports treatment retention and long-term recovery when paired with therapy.
- Evidence-based MOUD consistent with national guidelines.
- Smooth transition from transmucosal buprenorphine with minimal disruption.
Accepting Most Major Insurance Companies:
Ketamine offers fast, life-changing relief.
How Does It Work?
Ketamine therapy works by targeting the brain’s glutamate system, which plays a key role in mood, learning, and memory. Unlike traditional antidepressants that can take weeks, ketamine acts quickly—often within hours—by restoring healthy brain connections and boosting neuroplasticity. This helps “reset” areas of the brain affected by depression, making it easier to manage thoughts, emotions, and stress. It's fast, effective, and offers real hope for those who haven’t found relief elsewhere.
Don't Take our Word For It.
Third Party Studies:
- Weekly & Monthly Depot vs Daily Sublingual Buprenorphine — JAMA Internal Medicine
In a 24-week RCT, depot buprenorphine was noninferior to daily sublingual buprenorphine/naloxone for illicit-opioid negativity and response, with similar safety.
JAMA Network - Hydromorphone Challenge Blockade with Weekly Depot (CAM2038) — JAMA Psychiatry
Weekly depot produced robust blockade of opioid “drug-liking” and sustained withdrawal suppression in non–treatment-seeking adults.
PMC - Long-Term Safety & Retention with Weekly/Monthly Depot — National Library of Medicine (PMC)
Open-label data showed high treatment retention, low illicit opioid use, and acceptable tolerability over up to 48 weeks.
PMC - Patient Satisfaction: Depot vs Sublingual — JAMA Network
Patients randomized to depot reported higher satisfaction and lower treatment burden than sublingual therapy.
JAMA Network - BRIXADI Clinical Studies (Label Summary) — FDA
Two Phase 3 studies (double-blind active-control and open-label) support BRIXADI’s efficacy and safety in OUD.
FDA Access Data
- Phase 3 Noninferiority Trial Record (CAM2038 vs SL B/N) — ClinicalTrials.gov
Multicenter, double-blind, double-dummy design detailing endpoints, dosing, and analysis plan for depot vs sublingual.
ClinicalTrials.gov - ED Use of 7-Day Extended-Release Buprenorphine — National Library of Medicine (PMC)
Initial ED experience suggests 7-day depot can bridge induction and improve engagement in ongoing care.
PMC - PK–PD of Weekly Depot & Opioid Blockade — Neuropsychopharmacology
Depot exposures correlated with sustained hydromorphone blockade and reduced drug-liking ratings.
Nature - Evidence Review of Extended-Release MOUD — ICER
Independent review found ER buprenorphine offers clinical benefits and may improve adherence versus daily dosing.
ICER - Dose-Related Blockade During Chronic Buprenorphine — Johns Hopkins (repository)
Demonstrated buprenorphine’s dose-dependent blockade of hydromorphone effects, supporting the receptor-blockade mechanism.
pure.johnshopkins.edu
Real Stories, Real Healing, Real Mental Health Treatment
Progress You Can SEE
Happiness You Can FEEL
Contact Us
Get Help Now
Contact our TMS clinic to receive expert, personalized care and innovative treatments that effectively address your mental health needs.
Contact Form
"*" indicates required fields